Roivant Sciences (NASDAQ:ROIV) Insider Mayukh Sukhatme Sells 284,707 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 284,707 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75. Following the completion of the sale, the insider directly owned 18,630,739 shares of the company’s stock, valued at $675,364,288.75. This represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Mayukh Sukhatme also recently made the following trade(s):

• On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The stock was sold at an average price of $36.23, for a total value of $8,810,302.71.
• On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The stock was sold at an average price of $36.73, for a total transaction of $5,029,879.66.

Roivant Sciences Trading Up 3.1%

Shares of ROIV traded up $1.13 during trading hours on Tuesday, reaching $37.37. The company had a trading volume of 6,409,504 shares, compared to its average volume of 5,396,372. Roivant Sciences Ltd. has a 12-month low of $11.54 and a 12-month high of $37.46. The firm has a 50 day simple moving average of $34.16 and a 200-day simple moving average of $30.17. The company has a market capitalization of $26.99 billion, a price-to-earnings ratio of -70.51 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.04. The company had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.06 million. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. Sell-side analysts forecast that Roivant Sciences Ltd. will post -1.83 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on ROIV shares. TD Cowen reissued a “buy” rating on shares of Roivant Sciences in a research note on Thursday, August 6th. HC Wainwright lifted their target price on shares of Roivant Sciences from $34.00 to $41.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Citigroup upped their price target on shares of Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a report on Monday, August 10th. Bank of America reiterated a “neutral” rating on shares of Roivant Sciences in a research report on Friday, July 31st. Finally, Weiss Ratings lowered Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $35.14.

Institutional Trading of Roivant Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ROIV. Public Employees Retirement System of Ohio acquired a new position in Roivant Sciences in the 2nd quarter valued at about $4,936,000. Great Lakes Advisors LLC purchased a new stake in shares of Roivant Sciences during the second quarter worth about $3,815,000. Handelsbanken Fonder AB grew its holdings in shares of Roivant Sciences by 51.4% during the second quarter. Handelsbanken Fonder AB now owns 177,209 shares of the company’s stock worth $6,271,000 after buying an additional 60,200 shares in the last quarter. Assenagon Asset Management S.A. raised its position in shares of Roivant Sciences by 18.2% in the second quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company’s stock valued at $295,965,000 after buying an additional 1,286,464 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in shares of Roivant Sciences by 17.4% in the second quarter. GAMMA Investing LLC now owns 14,637 shares of the company’s stock valued at $518,000 after buying an additional 2,172 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.